Janux Therapeutics, Inc. (JANX) intrinsic value & 10-year financials
Janux Therapeutics, Inc. (JANX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 28.8% a year to $10.0M, with an average return on invested capital of -12.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $16.51
- Market cap
- $1.0B
- Revenue (FY2025)
- $10.0M
- Revenue growth (7-yr CAGR)
- 28.8%
- ROIC (10-yr avg)
- -12.5%
- Free cash flow (FY2025)
- -$83.3M
JANX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $10.0M | -$113.6M | -$1.83 | -$83.3M | -1576.7% | -20.5% |
| FY2024 | $10.6M | -$69.0M | -$1.28 | -$44.2M | -933.6% | -20.6% |
| FY2023 | $8.1M | -$58.3M | -$1.32 | -$52.4M | -902.9% | -22.7% |
| FY2022 | $8.6M | -$63.1M | -$1.52 | -$49.4M | -779.0% | -20.2% |
| FY2021 | $3.6M | -$32.7M | -$1.39 | -$18.5M | -905.4% | -21.2% |
| FY2020 | $0 | -$6.8M | — | — | — | 30.2% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Janux Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Janux Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -12.5% ROIC.
Janux Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Janux Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-60.78 per share.